Literature DB >> 3593475

In vitro antiviral activity of the 6-substituted 2-(3',4'-dichlorophenoxy)-2H-pyrano[2,3-b]pyridines MDL 20,610, MDL 20,646, and MDL 20,957.

M T Kenny, J K Dulworth, T M Bargar, H L Torney, M C Graham, A M Manelli.   

Abstract

The 6-substituted 2-(3',4'-dichlorophenoxy)-2H-pyrano[2,3-b]pyridines MDL 20,610 (6-SO2CH3), MDL 20,646 (6-Br), and MDL 20,957 (6-Cl) are potent antirhinovirus compounds with median plaque 50% inhibitory concentrations (IC1/2s) of 0.03, 0.006, and 0.006 micrograms/ml, respectively, against the 32 serotypes evaluated. The 6-halogenated analogs produced 99% reductions in progeny virion yields at concentrations as low as 0.004 micrograms/ml. However, these analogs perturbated HeLa cell metabolism at lower concentrations (at or above 5 micrograms/ml) than did the 6-methylsulfonyl analog (at or above 20 micrograms/ml). Compound MDL 20,610 was also active against human, simian, and bovine rotaviruses (cytopathic effect IC1/2s of 0.8 to 1.5 micrograms/ml) and possessed variable enterovirus and paramyxovirus activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3593475      PMCID: PMC180594          DOI: 10.1128/AAC.30.3.516

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Inhibition of uncoating of poliovirus by arildone, a new antiviral drug.

Authors:  J J McSharry; L A Caliguiri; H J Eggers
Journal:  Virology       Date:  1979-09       Impact factor: 3.616

2.  Simple method for measuring growth inhibition by interferon of cells in monolayer.

Authors:  H Schellekens; L W Stitz
Journal:  J Virol Methods       Date:  1980       Impact factor: 2.014

3.  Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B.

Authors:  M Tisdale; J W Selway
Journal:  J Antimicrob Chemother       Date:  1984-08       Impact factor: 5.790

4.  WIN 51711, a new systematically active broad-spectrum antipicornavirus agent.

Authors:  M A McKinlay
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

5.  Antiviral activity and mechanism of action of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860).

Authors:  H L Torney; J K Dulworth; D L Steward
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

6.  Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin.

Authors:  K Tobita; A Sugiura; C Enomote; M Furuyama
Journal:  Med Microbiol Immunol       Date:  1975-12-30       Impact factor: 3.402

7.  Enhancement of activity against influenza viruses by combinations of antiviral agents.

Authors:  F G Hayden; R G Douglas; R Simons
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  In vitro and in vivo antipicornavirus activity of some phenoxypyridinecarbonitriles.

Authors:  M T Kenny; J K Dulworth; H L Torney
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

9.  4',6-Dichloroflavan (BW683C), a new anti-rhinovirus compound.

Authors:  D J Bauer; J W Selway; J F Batchelor; M Tisdale; I C Caldwell; D A Young
Journal:  Nature       Date:  1981-07-23       Impact factor: 49.962

  9 in total
  10 in total

1.  Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity.

Authors:  K Andries; B Dewindt; J Snoeks; L Wouters; H Moereels; P J Lewi; P A Janssen
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

2.  Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 3.  Chemotherapy of rhinovirus colds.

Authors:  S J Sperber; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

4.  Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound.

Authors:  K Andries; B Rombaut; B Dewindt; A Boeyé
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

5.  Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation.

Authors:  B Rombaut; B Verheyden; K Andries; A Boeyé
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords; K van Eemeren; R Stokbroekx; P A Janssen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

7.  In vitro activity of R 61837, a new antirhinovirus compound.

Authors:  K Andries; B Dewindt; M De Brabander; R Stokbroekx; P A Janssen
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  Mechanism of action of the antiviral compound MDL 20,610.

Authors:  M T Kenny; H L Torney; J K Dulworth
Journal:  Antiviral Res       Date:  1988-07       Impact factor: 5.970

Review 9.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

Review 10.  The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.

Authors:  Judith M Rollinger; Michaela Schmidtke
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.